Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy
Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy
复制标题
程序性细胞死亡1配体1杂合性在非小细胞肺癌患者免疫治疗选择中的意义
DOI：
10.1002/cpt.360
复制
发表时间：
2016-09-01
影响因子：
6.7
通讯作者：
Dong, H.
中科院分区：
文献类型：
--
作者：
Mansfield, A. S.;Dong, H.
使用程序性细胞死亡1配体1(PD-L1)作为预测生物标志物来选择接受程序性细胞死亡1(PD-1)或PD-L1抑制剂治疗的非小细胞肺癌(NSCLC)患者受到阳性定义、检测间一致性以及肿瘤内和肿瘤间表达异质性的限制。尽管PD-L1的表达丰富了反应，但表达的缺乏并不排除临床益处。
The use of programmed cell death 1 ligand 1 (PD-L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD-1) or PD-L1 inhibitors in non-small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra- and intertumoral heterogeneity of expression. Although PD-L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.